Rein Therapeutics (RNTX) Competitors $1.88 -0.09 (-4.57%) As of 06/13/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock RNTX vs. ACTU, INMB, VTYX, DERM, LRMR, SGMT, ALTS, ALMS, TLSA, and ACRSShould you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Actuate Therapeutics (ACTU), INmune Bio (INMB), Ventyx Biosciences (VTYX), Journey Medical (DERM), Larimar Therapeutics (LRMR), Sagimet Biosciences (SGMT), Janone (ALTS), Alumis (ALMS), Tiziana Life Sciences (TLSA), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry. Rein Therapeutics vs. Its Competitors Actuate Therapeutics INmune Bio Ventyx Biosciences Journey Medical Larimar Therapeutics Sagimet Biosciences Janone Alumis Tiziana Life Sciences Aclaris Therapeutics Actuate Therapeutics (NASDAQ:ACTU) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking. Do insiders & institutionals have more ownership in ACTU or RNTX? 90.9% of Rein Therapeutics shares are owned by institutional investors. 69.3% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer ACTU or RNTX? Actuate Therapeutics received 3 more outperform votes than Rein Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformActuate TherapeuticsOutperform Votes3100.00% Underperform VotesNo VotesRein TherapeuticsN/AN/A Is ACTU or RNTX more profitable? Actuate Therapeutics' return on equity of 0.00% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A Rein Therapeutics N/A -74.08%-27.93% Does the media refer more to ACTU or RNTX? In the previous week, Rein Therapeutics had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 3 mentions for Rein Therapeutics and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.87 beat Rein Therapeutics' score of 0.30 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Actuate Therapeutics Very Positive Rein Therapeutics Neutral Which has higher earnings & valuation, ACTU or RNTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/ARein TherapeuticsN/AN/A-$15.73M-$2.86-0.66 Do analysts rate ACTU or RNTX? Actuate Therapeutics presently has a consensus target price of $20.50, indicating a potential upside of 136.99%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Actuate Therapeutics is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Rein Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryActuate Therapeutics beats Rein Therapeutics on 8 of the 11 factors compared between the two stocks. Get Rein Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNTX vs. The Competition Export to ExcelMetricRein TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.65M$6.87B$5.57B$8.50BDividend YieldN/A2.52%5.28%4.16%P/E Ratio-0.608.4326.6319.64Price / SalesN/A262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book1.336.536.964.60Net Income-$15.73M$143.25M$3.23B$248.06M7 Day Performance-6.00%-0.06%-1.13%-0.94%1 Month Performance-16.44%11.77%8.59%3.52%1 Year PerformanceN/A3.66%33.63%14.02% Rein Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNTXRein TherapeuticsN/A$1.88-4.6%N/AN/A$41.65MN/A-0.609News CoverageACTUActuate TherapeuticsN/A$8.96-1.4%$20.50+128.8%N/A$175.80MN/A0.0010Gap UpINMBINmune Bio2.0408 of 5 stars$7.62+3.7%$22.80+199.2%-15.2%$175.14M$50K-3.5010News CoveragePositive NewsVTYXVentyx Biosciences2.4012 of 5 stars$2.46+9.3%$10.00+306.5%-10.8%$175.06MN/A-1.0430News CoveragePositive NewsOptions VolumeHigh Trading VolumeDERMJourney Medical2.264 of 5 stars$7.39-2.0%$9.88+33.6%+26.3%$172.16M$56.24M-7.8690News CoverageAnalyst DowngradeShort Interest ↑LRMRLarimar Therapeutics2.5379 of 5 stars$2.68+8.9%$19.67+633.8%-70.3%$171.60MN/A-2.3330Short Interest ↓Gap DownSGMTSagimet Biosciences2.351 of 5 stars$5.56+16.3%$23.17+316.7%+72.7%$170.55M$2M-3.168High Trading VolumeALTSJanoneN/A$10.21+4.9%N/AN/A$169.92M$18.05M0.00170Short Interest ↑Gap DownALMSAlumis2.8608 of 5 stars$3.59+7.2%$24.86+592.4%N/A$169.52M$17.39M0.00N/APositive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionHigh Trading VolumeTLSATiziana Life Sciences0.9778 of 5 stars$1.43+1.4%N/A+112.9%$167.09MN/A0.008News CoverageACRSAclaris Therapeutics2.6747 of 5 stars$1.53-1.9%$9.71+534.9%+23.5%$165.67M$17.78M-2.94100Positive News Related Companies and Tools Related Companies ACTU Competitors INMB Competitors VTYX Competitors DERM Competitors LRMR Competitors SGMT Competitors ALTS Competitors ALMS Competitors TLSA Competitors ACRS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNTX) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNTX Stock Free RNTX Stock Alerts